HK1077582A1 - Aryl 5-thio beta-d-glucopyranside derivatives and remedies for diabetes containing sthe same - Google Patents

Aryl 5-thio beta-d-glucopyranside derivatives and remedies for diabetes containing sthe same

Info

Publication number
HK1077582A1
HK1077582A1 HK05109578A HK05109578A HK1077582A1 HK 1077582 A1 HK1077582 A1 HK 1077582A1 HK 05109578 A HK05109578 A HK 05109578A HK 05109578 A HK05109578 A HK 05109578A HK 1077582 A1 HK1077582 A1 HK 1077582A1
Authority
HK
Hong Kong
Prior art keywords
glucopyranside
remedies
aryl
derivatives
diabetes containing
Prior art date
Application number
HK05109578A
Other languages
English (en)
Inventor
Masakazu Sato
Hiroyuki Kakinuma
Hajime Asanuma
Original Assignee
Taiso Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiso Pharmaceutical Co Ltd filed Critical Taiso Pharmaceutical Co Ltd
Publication of HK1077582A1 publication Critical patent/HK1077582A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
HK05109578A 2002-08-09 2005-10-27 Aryl 5-thio beta-d-glucopyranside derivatives and remedies for diabetes containing sthe same HK1077582A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002233015 2002-08-09
JP2003097839 2003-04-01

Publications (1)

Publication Number Publication Date
HK1077582A1 true HK1077582A1 (en) 2006-02-17

Family

ID=31719867

Family Applications (2)

Application Number Title Priority Date Filing Date
HK05109578A HK1077582A1 (en) 2002-08-09 2005-10-27 Aryl 5-thio beta-d-glucopyranside derivatives and remedies for diabetes containing sthe same
HK05111661A HK1079532A1 (en) 2002-08-09 2005-12-17 Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK05111661A HK1079532A1 (en) 2002-08-09 2005-12-17 Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides

Country Status (19)

Country Link
US (2) US7414072B2 (fr)
EP (2) EP1528066A4 (fr)
JP (2) JP3813160B2 (fr)
KR (2) KR20050056194A (fr)
CN (2) CN1312165C (fr)
AU (2) AU2003254903B9 (fr)
BR (1) BR0310006A (fr)
CA (2) CA2478889A1 (fr)
HK (2) HK1077582A1 (fr)
HR (1) HRP20040814A2 (fr)
MX (2) MXPA05000725A (fr)
NO (2) NO20043733L (fr)
NZ (1) NZ535229A (fr)
PL (2) PL375298A1 (fr)
RU (1) RU2322449C2 (fr)
TW (2) TW200409778A (fr)
UA (1) UA77300C2 (fr)
WO (2) WO2004014931A1 (fr)
ZA (1) ZA200407187B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
AU2003301900A1 (en) * 2002-11-13 2004-06-03 Fumie Sato Antipruritic drug
EP1609799A4 (fr) * 2003-04-01 2008-10-29 Taisho Pharmaceutical Co Ltd Derives heteroaryle 5-thio-beta-d-glucopyranoside et medicaments contre le diabete contenant ces derives
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
DK2896397T4 (da) 2003-08-01 2020-11-16 Mitsubishi Tanabe Pharma Corp Nye forbindelser med hæmmende aktivitet mod natriumafhængig glukosetransportør
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
CN101010276B (zh) * 2004-07-26 2011-01-12 中外制药株式会社 环己烷衍生物、其前体药物及其盐、以及含有它的糖尿病治疗药
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
MY147375A (en) 2005-01-31 2012-11-30 Mitsubishi Tanabe Pharma Corp Indole derivatives
JP5073948B2 (ja) * 2005-01-31 2012-11-14 田辺三菱製薬株式会社 医薬組成物
EP1854806A1 (fr) * 2006-05-02 2007-11-14 MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Thioglycosides en tant que composés pharmaceutiques
JP2009167104A (ja) * 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd フェニル５−チオグリコシド化合物
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US7803778B2 (en) * 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
MX2008016231A (es) * 2006-06-29 2009-01-16 Taisho Pharma Co Ltd Compuesto de c-fenil 1-tioglucitol.
TWI418556B (zh) 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
FR2906247B1 (fr) * 2006-09-27 2008-12-26 Fournier S A Sa Lab Nouveaux derives de 5-thioxylopyranose
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
BRPI0719523A2 (pt) * 2006-10-13 2015-06-16 Chugai Pharmaceutical Co Ltd Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes
ES2397664T3 (es) 2006-12-04 2013-03-08 Janssen Pharmaceutica, N.V. Derivados de glucopiranósilo que contienen tienilo como antidiabéticos
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
WO2008072726A1 (fr) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. Dérivé de 1-phényl 1-thio-d-glucitol
US7795228B2 (en) * 2006-12-28 2010-09-14 Theracos, Inc. Spiroheterocyclic glycosides and methods of use
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
AU2008232419B2 (en) 2007-04-02 2013-06-20 Theracos, Inc. Benzylic glycoside derivatives and methods of use
EP2183263B1 (fr) * 2007-07-26 2011-10-26 Lexicon Pharmaceuticals, Inc. Procédés et composés utiles pour la préparation d'inhibiteurs de co-transporteur 2 de sodium-glucose
JP4809931B2 (ja) * 2007-08-23 2011-11-09 セラコス・インコーポレイテッド ベンジルベンゼン誘導体およびその使用方法
ES2647504T3 (es) 2007-09-10 2017-12-21 Janssen Pharmaceutica N.V. Proceso para la preparación de compuestos útiles como inhibidores de SGLT
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
JP6071198B2 (ja) 2008-07-15 2017-02-01 テラコス，インコーポレーテッド 重水素化ベンジルベンゼン誘導体及び使用方法
NZ591818A (en) 2008-08-22 2013-01-25 Theracos Inc Processes for the preparation of sglt2 inhibitors
JP4825322B1 (ja) * 2008-08-28 2011-11-30 ファイザー・インク ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN102482250B (zh) 2009-07-10 2014-11-19 詹森药业有限公司 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的结晶方法
CN102648196B (zh) 2009-10-14 2016-04-27 詹森药业有限公司 可用作sglt2的抑制剂的化合物的制备方法
PT2496583E (pt) 2009-11-02 2015-01-14 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
CN108354930A (zh) 2010-05-11 2018-08-03 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
WO2011153712A1 (fr) 2010-06-12 2011-12-15 Theracos, Inc. Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène
US10544135B2 (en) 2011-04-13 2020-01-28 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
SG11201406080VA (en) 2012-03-28 2014-11-27 Fujifilm Corp SALT OF 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINE
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
RU2633355C2 (ru) 2012-08-13 2017-10-12 Фуджифилм Корпорэйшн СИНТЕТИЧЕСКОЕ ПРОМЕЖУТОЧНОЕ СОЕДИНЕНИЕ 1-(2-ДЕЗОКСИ-2-ФТОР-4-ТИО-β-D-АРАБИНОФУРАНОЗИЛ)ЦИТОЗИНА, СИНТЕТИЧЕСКОЕ ПРОМЕЖУТОЧНОЕ СОЕДИНЕНИЕ ТИОНУКЛЕОЗИДА И СПОСОБ ИХ ПОЛУЧЕНИЯ
WO2014151871A2 (fr) 2013-03-14 2014-09-25 Tolero Pharmaceuticals, Inc. Inhibiteurs de jak2 et alk2 et leurs procédés d'utilisation
US20140303098A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA3175715A1 (fr) 2013-04-18 2014-10-23 Boehringer Ingelheim International Gmbh Composition pharmaceutique, methodes de traitement et utilisations associees
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
CN106061959B (zh) 2014-02-18 2018-11-09 富士胶片株式会社 四氢噻吩骨架型糖化合物的制造方法及四氢噻吩骨架型糖化合物
JP6204223B2 (ja) * 2014-02-19 2017-09-27 富士フイルム株式会社 チオピラノース化合物等の製造方法
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
WO2018043530A1 (fr) 2016-08-31 2018-03-08 富士フイルム株式会社 Agent antitumoral, activateur d'effet antitumoral et kit anti-tumoral
CA3089728C (fr) 2018-01-29 2023-01-10 Fujifilm Corporation Agent antitumoral contre le cancer biliaire et methode de traitement du cancer biliaire
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3055135B2 (ja) 1996-12-26 2000-06-26 田辺製薬株式会社 プロピオフェノン誘導体及びその製法
ES2176600T3 (es) * 1996-12-26 2002-12-01 Tanabe Seiyaku Co Derivado de la propiofenona y procedimientos para su preparacion.
DK1213296T3 (da) 1999-08-31 2004-08-16 Kissei Pharmaceutical Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf
FR2801055B1 (fr) * 1999-11-17 2002-02-08 Fournier Ind & Sante Derives de beta-d-5-thioxylose, procede de preparation et utilisation en therapeutique
NZ521369A (en) 2000-03-17 2004-07-30 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
ES2214432T3 (es) 2000-05-20 2004-09-16 Tesa Ag Utilizacion de un soporte de papel de elevada densidad como tira soporte en un material de revestimiento para una cinta adhesiva.
SK287811B6 (sk) * 2000-09-29 2011-10-04 Kissei Pharmaceutical Co., Ltd Glukopyranozyloxybenzylbenzénový derivát, farmaceutická kompozícia a ľudský SGLT2-inhibítor tento derivát obsahujúci a použitie tohto derivátu
DE60141156D1 (de) * 2000-11-02 2010-03-11 Ajinomoto Kk Neue pyrazolderivate und diese enthaltende mittel gegen diabetes
EP1354888B1 (fr) * 2000-12-28 2009-05-20 Kissei Pharmaceutical Co., Ltd. Derives de glucopyranosiloxypyrazole et leur utilisation dans des medicaments
CA2455300A1 (fr) 2001-06-20 2003-01-03 Kissei Pharmaceutical Co., Ltd. Derive heterocyclique azote, composition medicinale contenant ce derive, leur utilisation medicinale et intermediaire associe
US7439232B2 (en) 2003-04-01 2008-10-21 Taisho Pharmaceutical Co., Ltd. Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
EP1609799A4 (fr) 2003-04-01 2008-10-29 Taisho Pharmaceutical Co Ltd Derives heteroaryle 5-thio-beta-d-glucopyranoside et medicaments contre le diabete contenant ces derives

Also Published As

Publication number Publication date
KR20050018642A (ko) 2005-02-23
CN100341885C (zh) 2007-10-10
ZA200407187B (en) 2006-02-22
CA2478889A1 (fr) 2004-02-19
WO2004014930A1 (fr) 2004-02-19
MXPA04009265A (es) 2005-01-25
KR20050056194A (ko) 2005-06-14
PL372865A1 (en) 2005-08-08
UA77300C2 (en) 2006-11-15
US7414072B2 (en) 2008-08-19
PL375298A1 (en) 2005-11-28
US7250522B2 (en) 2007-07-31
US20050256317A1 (en) 2005-11-17
KR100588457B1 (ko) 2006-06-12
TW200406396A (en) 2004-05-01
JPWO2004014930A1 (ja) 2005-12-02
CN1675233A (zh) 2005-09-28
TWI274055B (en) 2007-02-21
EP1528066A1 (fr) 2005-05-04
MXPA05000725A (es) 2005-04-08
CN1312165C (zh) 2007-04-25
NZ535229A (en) 2006-05-26
CA2493491A1 (fr) 2004-02-19
BR0310006A (pt) 2005-02-15
US20050209309A1 (en) 2005-09-22
NO20043733L (no) 2004-10-20
JP3813160B2 (ja) 2006-08-23
AU2003254903A1 (en) 2004-02-25
EP1528066A4 (fr) 2007-05-02
HRP20040814A2 (en) 2005-06-30
AU2003254904A1 (en) 2004-02-25
RU2322449C2 (ru) 2008-04-20
TW200409778A (en) 2004-06-16
RU2004135914A (ru) 2005-05-10
CN1639180A (zh) 2005-07-13
AU2003254903B9 (en) 2008-08-21
HK1079532A1 (en) 2006-04-07
AU2003254903B2 (en) 2008-07-31
JPWO2004014931A1 (ja) 2005-12-02
WO2004014931A1 (fr) 2004-02-19
NO20050650L (no) 2005-03-04
EP1541578A1 (fr) 2005-06-15

Similar Documents

Publication Publication Date Title
HK1077582A1 (en) Aryl 5-thio beta-d-glucopyranside derivatives and remedies for diabetes containing sthe same
PL377656A1 (pl) Ligandy Ó2Ű do różnych zastosowań farmaceutycznych
IL162548A0 (en) 4-Oxoquinoline derivatives and pharmaceutical compositions containing the same
EP1609799A4 (fr) Derives heteroaryle 5-thio-beta-d-glucopyranoside et medicaments contre le diabete contenant ces derives
IL166482A0 (en) Dihydropyrazolopyridine derivatives and pharmaceutical compositions containing the same
IL178297A0 (en) Hydrazide derivatives and pharmaceutical compositions containing the same
HK1082249A1 (en) Isoquinoline derivatives having kinasae inhibitoryactivity and drugs containing the same
IL173602A0 (en) Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same
IL173627A0 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same
HK1087103A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
IL173051A0 (en) N-glucoside derivatives and pharmaceutical compositions containing the same
IL164209A0 (en) Pyrazole derivatives and pharmaceutical compositions containing the same
IL166620A0 (en) Pyrazole derivatives and pharmaceutical compositions containing the same
IL171997A0 (en) Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same
IL175214A0 (en) 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same
PL377791A1 (pl) Pochodne 3-aminopiperydyny i sposoby ich wytwarzania
IL172159A0 (en) 2-oxo-pyridine derivatives and pharmaceutical compositions containing the same
AU2003291024A1 (en) Rhodanine derivatives and pharmaceutical compositions containing them
AU2003289440A1 (en) Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
PL359321A1 (en) New salt perindopryl and pharmaceutical composunds containing it
AU2003234929A1 (en) Therapeutic agent for diabetes
AU2003279442A1 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2003205558A1 (en) Thioibotenic acid and derivatives thereof
AU2003208673A1 (en) Pacifier for administering flavour substances
AU2003246143A1 (en) Polypeptide agent for inhibiting sars coronavirus and its derivatives and use thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110808